[CAS NO. 79350-37-1] Cefixime

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [79350-37-1]

Catalog

HY-B1381

Brand

MCE

CAS

79350-37-1

DESCRIPTION [79350-37-1]

Overview

MDL	MFCD00865020
Molecular Weight	453.45
Molecular Formula	C16H15N5O7S2
SMILES	O=C(C(N12)=C(C=C)CS[C@]2([H])[C@H](NC(/C(C3=CSC(N)=N3)=N\OCC(O)=O)=O)C1=O)O

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]Biomed Res Int. 2018 Jul 2;2018:3579832.

Summary

Cefixime is an antibiotic and a third generation cephalosporin antibiotic , useful for the treatment of a number of bacterial infections.

IC50 & Target

β-lactam

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03329547	GlaxoSmithKline	Infections, Bacterial	January 11, 2018	Phase 1
NCT03969758	Postgraduate Institute of Medical Education and Research	Liver Abscess	July 2019	Phase 3
NCT03840811	National Institute of Allergy and Infectious Diseases (NIAID)	Gonococcal Infection	April 23, 2017	Phase 1
NCT01949363	National Institute of Allergy and Infectious Diseases (NIAID)	Gonorrhoea	December 2013	Phase 1
NCT01072136	National Institute of Allergy and Infectious Diseases (NIAID)	Vaginitis Bacterial\|Cervicitis	March 2010	Phase 3
NCT02224040	Sheba Medical Center	Typhoid Fever	August 2013	Phase 4
NCT05294588	University of North Carolina, Chapel Hill\|National Institute of Allergy and Infectious Diseases (NIAID)	Gonorrhea Male	April 18, 2022	Phase 2
NCT03660488	University of California, Los Angeles\|AIDS Healthcare Foundation	Syphilis\|Early Syphilis	September 3, 2018	Phase 2
NCT00093353	Children´s Hospital Los Angeles\|National Cancer Institute (NCI)	Diarrhea\|Drug+Agent Toxicity by Tissue+Organ\|Neuroblastoma	May 2004	Phase 1
NCT04982861	PT Bernofarm\|PT Pharma Metric Labs	Drug Use	June 15, 2020	Not Applicable
NCT00004216	Vion Pharmaceuticals\|National Cancer Institute (NCI)	Unspecified Adult Solid Tumor, Protocol Specific	August 1999	Phase 1
NCT02596503	University of Colorado, Denver\|University of Kentucky	Relapsed Solid Tumors\|Refractory Solid Tumors	October 21, 2015	Phase 1
NCT05216744	Haiphong University of Medicine and Pharmacy	Neisseria Gonorrhoeae Infection\|Chlamydia Trachomatis Infection	July 15, 2021	Phase 2
NCT01595529	National Institute of Allergy and Infectious Diseases (NIAID)	Urinary Tract Infection	May 18, 2012	Phase 2
NCT02021006	Fondazione IRCCS Ca´ Granda, Ospedale Maggiore Policlinico\|Ministero della Salute, Italy\|IL Sogno di Stefano	Vesicoureteral Reflux\|Renal Hypodysplasia, Nonsyndromic, 1\|Chronic Kidney Disease	December 2013	Phase 3
NCT04958122	University of Southern California\|AIDS Healthcare Foundation\|Universidad Peruana Cayetano Heredia	Syphilis\|Human Immunodeficiency Virus	June 20, 2021	Phase 3
NCT04349826	Oxford University Clinical Research Unit, Vietnam\|University of Oxford\|Medical Research Council\|Department for International Development, United Kingdom\|Wellcome Trust	Typhoid Fever	May 23, 2021	Phase 4
NCT00786669	Children´s Hospital Medical Center, Cincinnati	Solid Tumor	October 2008	Phase 1
NCT03752112	World Health Organization	Syphilis Female	November 22, 2019	Phase 1\|Phase 2
NCT02708992	National Institute of Allergy and Infectious Diseases (NIAID)	Gonorrhoea	April 28, 2016	Phase 1
NCT05027893	University of Novi Sad	Postoperative Complications\|Antibiotic Reaction\|Antibiotic Side Effect\|Antibiotic Resistant Infection\|Antibiotic Resistant Strain\|Infection, Bacterial\|Infection, Laboratory	June 7, 2019	Not Applicable

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 220.53 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2053 mL	11.0266 mL	22.0531 mL
5 mM	0.4411 mL	2.2053 mL	4.4106 mL
10 mM	0.2205 mL	1.1027 mL	2.2053 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (5.51 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (5.51 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.51 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-[(carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-, (6R,7R)-

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)[(carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-, [6R-[6α,7β(Z)]]-

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-(2-amino-4-thiazolyl)[(carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-, (6R,7R)-

(6R,7R)-7-[[(2Z)-2-(2-Amino-4-thiazolyl)-2-[(carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

FK 027

FR 17027

Cefixime

CL 284635

Oroken

Cephoral

Suprax

Unixime

Cefixoral

Cefspan

Cefixim

(-)-Cefixim

Loprax

Cefiximine

Suprax (antibiotic)

Fixitil

Ximacef

Cefexy

Hifen

Taxim-O

Ceftas

Cefoceb

Zifi

Fixx